Valuation: Hemostemix Inc.

Market Cap 11.63M 8.31M 7.42M 6.86M 6.22M 789M 11.82M 82.54M 32.68M 414M 31.2M 30.54M 1.3B P/E 2024
-4.36x
P/E 2025 -3.12x
Enterprise Value 14.49M 10.36M 9.25M 8.55M 7.75M 983M 14.73M 103M 40.72M 515M 38.88M 38.05M 1.62B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
83.37%
Yield 2024 *
-
Yield 2025 -
1 week-8.33%
Current month-8.33%
1 month-15.38%
3 months-8.33%
6 months-21.43%
Current year-38.89%
1 week 0.05
Extreme 0.05
0.06
1 month 0.05
Extreme 0.05
0.08
Current year 0.04
Extreme 0.04
0.11
1 year 0.04
Extreme 0.04
0.11
3 years 0.04
Extreme 0.035
0.42
5 years 0.04
Extreme 0.035
0.42
10 years 0
Extreme 0
5
Manager TitleAgeSince
Chief Executive Officer - 2020-02-09
Director of Finance/CFO - 2020-03-04
Chief Tech/Sci/R&D Officer - 2021-10-13
Director TitleAgeSince
Director/Board Member - 2019-11-25
Director/Board Member 67 2020-02-08
Director/Board Member - 2020-04-07
Date Insider Type Main position Quantity % Market Cap. Importance
7/30/26 Option

Chairman

525,000 0.2654%
7/22/26 Option

Director

385,000 0.1946%
7/22/26 Option

Founder

1,730,000 0.8746%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-8.33%-45.00%-45.00% 8.31M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
-0.38%+5.68%+38.39%+28.35% 23.67B
+1.19%-4.98%+26.31%-0.76% 23.97B
Average +0.25%+1.34%+38.77%+122.30% 38.31B
Weighted average by Cap. +0.39%+2.73%+46.02%+142.83%

Financials

2024 2025
Net sales - -
Net income -2.62M -1.87M -1.67M -1.54M -1.4M -178M -2.66M -18.57M -7.35M -93.04M -7.02M -6.87M -293M -4.71M -3.37M -3.01M -2.78M -2.52M -320M -4.79M -33.46M -13.25M -168M -12.65M -12.38M -528M
Net Debt 4.23M 3.03M 2.7M 2.5M 2.26M 287M 4.3M 30.03M 11.89M 150M 11.35M 11.11M 474M 2.86M 2.05M 1.83M 1.69M 1.53M 194M 2.91M 20.31M 8.04M 102M 7.68M 7.51M 321M
Projected Income Statement - Annual - Hemostemix Inc.
Logo Hemostemix Inc.
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Employees
-
Date Price Change Volume
26-10-23 $0.0550 0.00% 28,274
26-10-22 $0.0550 -8.33% 2,000
26-10-21 $0.0600 +9.09% 1,000
26-10-20 $0.0550 0.00% 111,327
26-10-19 $0.0550 -8.33% 2,074